UNSPSC 51313510: Texacromil

This classification denotes a mast cell stabilizer, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2B562K7K56. European Medicines Agency schedules Texacromil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10957MIG. Texacromil generally arises in the molecular formula C14H14O6S.

UNSPSC 51313510 Texacromil, a Commodity code, covers naloxone, drug deactivation systems, and related pharmaceutical products that state and local governments procure for public health, emergency response, and community health initiatives. The code encompasses both controlled-substance management supplies (such as drug deactivation systems) and life-safety pharmaceuticals (such as naloxone for opioid overdose reversal), as well as broader generic pharmaceuticals and over-the-counter products distributed through state and local health agencies and cooperative purchasing vehicles. Issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions and authorized wholesale distributors.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting with pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. Vendors under MMCAP must supply through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), maintain commercial general liability of at least $5 million per occurrence, and comply with current Good Manufacturing Practices and Drug Supply Chain Security Act requirements.